CRISPR Therapeutics (CRSP) has been making waves lately, especially after announcing promising early clinical data for its CTX310 program, a gene-editing therapy aimed at tackling cardiovascular ...

Horses with genomic edits to make them run faster have been banned from polo, but a zoo of CRISPR-edited animals is gaining ...

Gene-edited pancreatic cells have been transplanted into a patient with type 1 diabetes for the first time. They produced ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

The new system developed by Professor Chad Mirkin delivers CRISPR machinery more safely and effectively into cells.

In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. CRISPR Therapeutics AG ...

Researchers engineered and screened dozens of base editors to precisely target a single mutation without editing other portions of the DNA.

Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics (NASDAQ:CRSP), and it's something market players shouldn't ignore. Our tracking of public options records at ...

CRISPR stock offers bold investment potential and how strategic portfolio management can boost resilience and long-term ...

CRISPR Therapeutics AG ( NASDAQ: CRSP) H.C. Wainwright 27th Annual Global Investment Conference September 8, 2025 4:30 PM EDT ...

A study, published in the journal Frontiers in Genome Editing, outlines a method for editing single plant cells from sterile ...